1. (A) Frequencies of CYP2C19 genotypes in patients with eradication and noneradication of H. pylori infection by triple PPI/amoxicillin/clarithromycin therapy. Note that most (>97%) patients with noneradication of H. pylori had EM genotypes of CYP2C19 (RM or IM), while only one PM patient belonged to the noneradication group. (B) Frequencies of clarithromycin-sensitive and -resistant strains of H. pylori in patients with and without eradication of H. pylori infection achieved with triple PPI/amoxicillin/clarithromycin therapy. Note that more than half (54.3%) of patients without eradication of H. pylori were infected with a clarithromycin-resistant strain of H. pylori, while only 6.2% of patients with eradication of H. pylori were infected with a clarithromycin-resistant strain of H. pylori. See the legend of Figure 17A–2 for the abbreviations.
Source: Chapter 17A. Pharmacogenomics of Gastrointestinal Drugs: Focus on Proton Pump Inhibitors, Pharmacogenomics: An Introduction and Clinical Perspective
Citation: Bertino JS, Jr, DeVane C, Fuhr U, Kashuba AD, Ma JD. Pharmacogenomics: An Introduction and Clinical Perspective; 2013 Available at: Accessed: November 13, 2017
Copyright © 2017 McGraw-Hill Education. All rights reserved